872 followers
Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. https://t.co/8zLB9cYX0d
Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. https://t.co/8zLB9cYX0d
RT @JNeurooncol: Na et al. report the utility of the TruSight Tumor 170 panel-based Next Generation Sequencing (NGS) assay for genotyping d…
Not sure how clinically useful this is. Potentially targetable mutations/ fusions not included. What say you #btsm?
RT @JNeurooncol: Na et al. report the utility of the TruSight Tumor 170 panel-based Next Generation Sequencing (NGS) assay for genotyping d…